Patents by Inventor Henrik Dalb.o slashed.ge

Henrik Dalb.o slashed.ge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5693518
    Abstract: An enzyme exhibiting xylanase activity, which enzyme is immunologically reactive with an antibody raised against a purified xylanase derived from Aspercgillus aculeatus, CBS 101.43. The enzyme may be used for degrading plant cell wall components, e.g., in the preparation of feed, in baking, in the paper and pulp industry and in connection with separation of wheat into starch and gluten.
    Type: Grant
    Filed: February 15, 1996
    Date of Patent: December 2, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Lene Venke Kofod, Markus Sakari Kauppinen, Stephan Christgau, Hans Peter Heldt-Hansen, Henrik Dalb.o slashed.ge, Lene Nonboe Andersen, Joan Qi Si, Tina Sejersg.ang.rd Jacobsen, Niels Munk, Anette Mullertz
  • Patent number: 5691168
    Abstract: This invention is directed to isolated DNA sequences encoding AlaGlu-IGF-1, as well as vectors and microorganisms comprising such sequences.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: November 25, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Lars Skriver, Kim Ry Hejn.ae butted.s, Henrik Dalb.o slashed.ge
  • Patent number: 5691169
    Abstract: A desired protein having the formula:A-B-C-Pwhereina) A is Lys or Arg, and B and C are arbitrary amino acids, orb) A is an arbitrary amino acid different from Pro, Lys and Arg, and B and/or C is Pro,is produced from a biosynthetically formed amino acid extended protein having the formula:X-A-B-C-Pwherein A, B, C and P are as defined above, and X is an amino acid sequence with an even number of amino acids, of which the first one, seen from the N-terminal end, is different from Lys and Arg, all other uneven amino acids are different from Pro, Lys and Arg, and all even amino acids are different from Pro, by reaction with the enzyme dipeptidyl aminopeptidase (DAP I). The desired protein is obtained in a pure state. Thus, e.g. hGH without content of Met-hGH may be produced by the process.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: November 25, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Dalb.o slashed.ge, John Pedersen, Thorkild Christensen, J.o slashed.rli Winnie Ringsted, Torben Ehlern Jessen
  • Patent number: 5679552
    Abstract: A desired protein having the formula:A--B--C--Pwhereina) A is Lys or Arg, and B and C are arbitrary amino acids, orb) A is an arbitrary amino acid different from Pro, Lys and Arg, and B and/or C is Pro,is produced from a biosynthetically formed amino acid extended protein having the formula:X--A--B--C--Pwherein A, B, C and P are as defined above, and X is an amino acid sequence with an even number of amino acids, of which the first one, seen from the N-terminal end, is different from Lys and Arg, all other uneven amino acids are different from Pro, Lys and Arg, and all even amino acids are different from Pro, by reaction with the enzyme dipeptidyl aminopeptidase (DAP I). The desired protein is obtained in a pure state. Thus, e.g. hGH without content of Met-hGH may be produced by the process.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: October 21, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Dalb.o slashed.ge, John Pedersen, Thorkild Christensen, J.o slashed.rli Winnie Ringsted, Torben Ehlern Jessen
  • Patent number: 5667531
    Abstract: The present invention relates to isolated nucleic acid constructs containing a sequence encoding a polyporus laccase, and the laccase proteins encoded thereby.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 16, 1997
    Assignees: Novo Nordisk A/S, Novo Nordisk Biotech, Inc.
    Inventors: Debbie Sue Yaver, Feng Xu, Henrik Dalb.o slashed.ge, Palle Schneider, Dorrit A. Aaslyng
  • Patent number: 5635604
    Abstract: A desired protein having the formula:A-B-C-P,wherein (a) A is Lys or Arg, and B and C are arbitrary amino acids, or (b) A is an arbitrary amino acid different from Pro, Lys, and Arg, and B and/or C is Pro is produced from a biosynthetically formed amino-terminally extended protein having the formula:X-A-B-C-P,wherein A, B, C are defined above, and X is an amino acid sequence with an even number of amino acids, of which the first amino acid, seen from the N-terminal end, is different from Lys and Arg, all other am/no acids are different from Pro, Lys and Arg, and all even amino acids are different from Pro, by reaction with the enzyme dipeptidyl aminopeptidase (DAP I). The desired protein is obtained in a pure state. Specifically, P is human growth hormone (hGH). Thus, compositions of hGH may be produced without the presence of Met-hGH.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: June 3, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Dalb.o slashed.ge, John Pedersen, Thorkild Christensen, J.o slashed.rli W. Ringsted, Torben E. Jessen
  • Patent number: 5633352
    Abstract: A desired protein having the formula:A-B-C-Pwhereina) A is Lys or Arg, and B and C are arbitrary amino acids, orb) A is an arbitrary amino acid different from Pro, Lys and Arg, and B and/or C is Pro,is produced from a biosynthetically formed amino acid extended protein having the formula:X-A-B-C-Pwherein A, B, C and P are as defined above, and X is an amino acid sequence with an even number of amino acids, of which the first one, seen from the N-terminal end, is different from Lys and Arg, all other uneven amino acids are different from Pro, Lys and Arg, and all even amino acids are different from Pro, by reaction with the enzyme dipeptidyl aminopeptidase (DAP I). The desired protein is obtained in a pure state. Thus, e.g. hGH without content of Met-hGH may be produced by the process.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: May 27, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Dalb.o slashed.ge, John Pedersen, Thorkild Christensen, J.o slashed.rli W. Ringsted, Torben E. Jessen
  • Patent number: 5624835
    Abstract: The molecular characteristics and a partial amino acid sequence of an endo-.beta.-1,4-glucanase obtainable from Aspergillus aculeatus are described, as well as corresponding recombinant DNA sequences, vectors, and transformed hosts. Use of the endo-.beta.-1,4-glucanase or a pectinase preparation enriched with the endo-.beta.-1,4-glucanase for degradation or modification of plant cell walls is described.
    Type: Grant
    Filed: October 5, 1994
    Date of Patent: April 29, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Kurt Dorreich, Flemming M. Christensen, Yvette Schnell, Marcel Mischler, Henrik Dalb.o slashed.ge, Hans P. Heldt-Hansen
  • Patent number: 5618697
    Abstract: A process for producing ripe human growth hormone is described which comprises introducing into bacteria a recombinant DNA vector comprising a DNA sequence encoding an amino-terminal extended human growth hormone which amino-terminal extension has a negatively charged amino acid sequence and has an even number of amino acids, growing the bacteria such that the amino-terminal extended human growth is expressed, separating the amino-terminal extended human grown hormone from contaminants, cleaving the amino-terminal extension with dipeptidyl aminopeptidase I to obtain ripe human growth hormone and isolating the ripe human growth hormone produced.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: April 8, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Dalb.o slashed.ge, John Pedersen, Thorkild Christensen, J.o slashed.rli W. Ringsted, Torben E. Jessen
  • Patent number: 5610048
    Abstract: The xylanase is characterized by several partial amino acid sequences and is immunoreactive with an antibody raised against a purified xylanase derived from Humicola insolens, DSM 1800. This xylanase preparation is practically free of cellulase xylanase and is well suited for treatment of paper pulp, as a baking agent and as an additive to fodder.
    Type: Grant
    Filed: September 21, 1993
    Date of Patent: March 11, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Martin Schulein, Torben Halkier, Hans P. Heldt-Hansen, Henrik Dalb.o slashed.ge, Lars S. Pedersen
  • Patent number: 5585256
    Abstract: The present invention relates to rhamnogalacturon acetyl esterases derived from Aspergillus aculeatus and DNA Sequences encoding the enzymes. The present invention also relates to the use of rhamnogalacturon acetyl esterases for degrading modified hairy region.
    Type: Grant
    Filed: October 5, 1994
    Date of Patent: December 17, 1996
    Assignee: Novo Nordisk A/S
    Inventors: Kurt Dorreich, Flemming M. Christensen, Yvette Schnell, Marcel Mischler, Henrik Dalb.o slashed.ge, Hans P. Heldt-Hansen
  • Patent number: 5538884
    Abstract: The present invention relates to rhamnogalacturonases derived from a strain of Aspergillus japonicus which (a) has a pH-optimum between 6.5 and 7.0; (b) retains at least 80% of the maximal activity throughout the pH range of 5.5-12; (c) has a temperature optimum of about 40.degree. C.; and (d) retains at least 80% of the maximal activity throughout the temperature range of 20.degree.-60.degree. C. The present invention relates to rhamnogalacturonases derived from a stain of Aspergillus aculeatus which (a) has a pH-optimum of about 5.0; (b) retains at least 80% of the maximal activity throughout the pH range of 3-6.5; (c) has a temperature optimum of about 40.degree. C.; and (d) retains at least 80% of the maximal activity throughout the temperature range of 5.degree.-50.degree. C.
    Type: Grant
    Filed: December 15, 1993
    Date of Patent: July 23, 1996
    Assignee: Novo Nordisk A/S
    Inventors: Kurt D orreich, Henrik Dalb.o slashed.ge, Jan M. Mikkelsen, Flemming M. Christensen, Torben Halkier